Inhibikase Therapeutics Inc
NASDAQ:IKT

Watchlist Manager
Inhibikase Therapeutics Inc Logo
Inhibikase Therapeutics Inc
NASDAQ:IKT
Watchlist
Price: 1.62 USD 5.19% Market Closed
Market Cap: 196.5m USD
Section:
 

Relative Value

IKT doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of IKT.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IKT Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

N/A
P/S
P/S
Price to Sales
N/A
vs History
vs Industry
21
Median 3Y
591.2
Median 5Y
596.7
Industry
7.9
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-10
Median 5Y
-19.1
Industry
23.7
Forward
-3.1
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-14
Median 5Y
-20.6
Industry
22
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-13.7
Median 5Y
-20.5
Industry
23.8
More Details
2.7
P/B
P/B
Price to Book Value
2.7
vs History
85
vs Industry
50
Median 3Y
12.3
Median 5Y
21.3
Industry
3.3
More Details
N/A
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
52
Median 3Y
540.3
Median 5Y
578.2
Industry
8.3
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
30
Median 3Y
-8.3
Median 5Y
-18.2
Industry
6.4
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
28
Median 3Y
-8.3
Median 5Y
-18.1
Industry
7
Forward
-2.2
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
32
Median 3Y
-9.6
Median 5Y
-19.5
Industry
8.3
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
28
Median 3Y
-9.6
Median 5Y
-19.3
Industry
6.5
More Details
72.1
EV/IC
EV/IC
Enterprise Value to IC
72.1
vs History
67
vs Industry
7
Median 3Y
297.6
Median 5Y
449.2
Industry
5.7
More Details

Multiples Across Competitors

IKT Competitors Multiples
Inhibikase Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Inhibikase Therapeutics Inc
NASDAQ:IKT
196.5m USD 0 -4.1 -2.3 -2.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 738 486.8 -160 354 -194 720.9 -192 498.9
US
Abbvie Inc
NYSE:ABBV
402B USD 6.7 171.2 16.6 23.5
US
Amgen Inc
NASDAQ:AMGN
175B USD 4.9 25 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
148.8B USD 5.1 18.3 12.3 12.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.8B USD 9.9 31.5 23.1 24.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 088.1 -532.8 -580.2 -564.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD 5.6 17.3 16.5 18.7
AU
CSL Ltd
ASX:CSL
85.8B AUD 3.7 19 12.8 16
NL
argenx SE
XBRU:ARGX
44.3B EUR 14.5 34 58.7 60.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.6B USD 16.1 1 184.3 155.5 188.6
P/S Multiple
Revenue Growth P/S to Growth
US
Inhibikase Therapeutics Inc
NASDAQ:IKT
Average P/S: 3 374 064.1
Not Available 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 738 486.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 088.1
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
NL
argenx SE
XBRU:ARGX
14.5
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.1
46%
0.3
P/E Multiple
Earnings Growth PEG
US
Inhibikase Therapeutics Inc
NASDAQ:IKT
Average P/E: 187.6
Negative Multiple: -4.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 354 N/A N/A
US
Abbvie Inc
NYSE:ABBV
171.2
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.3
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
9%
1.9
AU
CSL Ltd
ASX:CSL
19
11%
1.7
NL
argenx SE
XBRU:ARGX
34
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 184.3
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Inhibikase Therapeutics Inc
NASDAQ:IKT
Average EV/EBITDA: 39.2
Negative Multiple: -2.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 720.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
NL
argenx SE
XBRU:ARGX
58.7
839%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
155.5
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Inhibikase Therapeutics Inc
NASDAQ:IKT
Average EV/EBIT: 45.2
Negative Multiple: -2.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 498.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.5
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.7
13%
1.4
AU
CSL Ltd
ASX:CSL
16
11%
1.5
NL
argenx SE
XBRU:ARGX
60.3
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
188.6
N/A N/A

See Also

Summary
IKT intrinsic value, competitors valuation, and company profile.
DCF Valuation
IKT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IKT stock valuation using valuation multiples.
Wall Street Estimates
IKT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IKT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.